Lansoprazole transdermal patch
By using a full film, limiting frame and fluoroscopic structure in lansoprazole transdermal patch, the skin irritation, adhesion, and instability of drug release of existing transdermal patches is solved, and the problem of skin irritation, adhesion and instability of drug release of existing transdermal patches is achieved. Higher viscosity and ease of use.
Patent Information
- Application Number
- CN202420905668.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-28
- Publication Date
- 2024-12-27
- Estimated Expiration
- 2034-04-28
AI Technical Summary
In use, existing transdermal patches can easily cause skin irritation, environmental adhesion, unstable drug release and liquid outflow, especially patches with high viscosity and high humidity can easily cause damage and inconvenience to the skin.
A lansoprazole transdermal patch was designed, using a full film and a limit frame, and the perspective film fixed patch body, the side film and the full film were made of thin transparent plastic material, which increased adhesion and reduced the probability of liquid outflow. The release paper and sticker structure facilitates use and observe patch status.
It improves the viscosity and sealing of the patch, reduces damage to the skin, enhances the convenience of use, and avoids the problems of liquid outflow and adhesion being affected by the environment.
Smart Images
Figure CN222238319U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to the technical field of transdermal patches, in particular to a lansoprazole transdermal patch. Background Art
[0002] Existing transdermal patches still have the following disadvantages in actual use:
[0003] ① Due to the barrier function of the skin and the molecular characteristics of the drug, only a few drugs are suitable for administration in the form of transdermal patches. ② Reservoir-type transdermal patches have the risk of internal drug leakage out of the package. If the membrane that controls the release rate is damaged during use, a large amount of drug will be suddenly released, causing serious toxic and side effects. ③ Because it takes a certain amount of time to reach the maximum blood drug concentration, transdermal patches are not suitable for emergency situations that require rapid onset of action. ④ The adhesion of transdermal patches may be affected by environmental factors or the site of use (such as humidity, temperature, and skin oiliness).
[0004] For example, the Granisetron transdermal patch is the first transdermal patch launched in China for the treatment of chemotherapy-induced nausea and vomiting. It is effective in preventing nausea and vomiting caused by moderate and high-level emetogenic tumor chemotherapy drugs. In many clinical trials at home and abroad, the Granisetron transdermal patch has shown clinical efficacy that is no less than that of the oral Granisetron preparation, and can stably prevent nausea and vomiting for up to 7 days.
[0005] During clinical use, two problems were found with the granisetron transdermal patch: patch shedding and skin irritation.
[0006] 1. The patch may curl or not fit well, which may affect the efficacy. Oily skin, sweat and hair may affect the fit of the transdermal patch and the efficacy. Therefore, when using the granisetron transdermal patch, you should choose a clean, dry area with sparse hair and stick it on the clean, dry, intact and healthy skin on the outer side of the upper arm. It should not be pasted on red, irritated or damaged skin, and moisturizing oil should not be used, and sweating should be avoided as much as possible.
[0007] 2. Skin irritation The transdermal patch may cause a certain amount of skin irritation, and the area where the patch is applied may experience redness, swelling, itching, and photosensitivity. Patients with sensitive skin who experience itching and swelling with other patches will experience the above symptoms more severely when using the transdermal patch. But generally speaking, the redness, swelling, and itching caused by the granisetron transdermal patch are relatively mild. In addition, exposure to light may cause skin discomfort to the area where the transdermal patch is applied. The area where the transdermal patch is applied should not be exposed to direct sunlight during the application period and within 10 days after removal. It is recommended that patients cover the application area with their sleeves.
[0008] Another example: the existing public document - CN220193582U, discloses an easily peelable external transdermal patch, including a lubricating bag, a side patch and a patch body, the side patches are evenly arranged on the four sides of the patch body, the upper surface of the side patches is evenly arranged with placement grooves, the four placement grooves are each provided with a lubricating bag, one end of the four lubricating bags is connected to one side of the side patch, the outer surface of the placement groove is covered with an outer sticker, and the outer sticker is applied to the outer side of the side patch. The device is provided with a lubricating bag, an outer sticker, a placement groove and a water hole, so that the device is easy to peel off, which solves the problem of the prior art that it is difficult to peel off during use and is easy to cause harm to the user. When not in use, the lubricating bag is placed in the placement groove and covered by the outer sticker without affecting the appearance. When the outer sticker is applied, the tension of the outer sticker can ensure that the lubricating bag is not crushed. The above application increases the convenience of peeling off the transdermal patch by connecting the lubricating bag to the adhesive tape. Since the patch is pasted on the skin and has a high viscosity, it is easy to cause harm to the user's skin. Moreover, the patch has been adhered to the skin, and the lubricating oil needs a long time to moisten the skin. With a low viscosity, the lubricating oil is easy to fall off and is also easy to touch during use, which causes great inconvenience during use. Among them, for patches with high wettability, liquid is easy to flow out. Utility Model Content
[0009] The utility model aims to provide a lansoprazole transdermal patch to solve the problem that the patch is pasted on the skin, has a high viscosity, is easy to cause damage to the user's skin, and the patch is already adhered to the skin, and the lubricant needs a long time to moisten the skin, has a low viscosity, and is easy to fall off, and is also easy to touch during use, which causes great inconvenience during use, among which, for a patch with high wettability, it is easy for liquid to flow out.
[0010] In order to achieve the above-mentioned purpose, the utility model provides the following technical solutions: a lansoprazole transdermal patch, comprising a full film, the middle of the full film is connected to a limiting frame, the middle of the limiting frame is connected to a transparent film, the outer side of the full film is connected to a side film, the front side of the transparent film is connected to a patch body and a first sticker, and the side film is folded on the first sticker.
[0011] Furthermore, the side films, the full film and the perspective film are all made of thin and transparent plastic materials and have a certain elasticity, and the side films are fixed on the full film.
[0012] Furthermore, a second sticker is attached to one end of the side film away from the full film, and the full film is fixedly connected to the limiting frame, wherein the thickness of the side film and the first sticker are both smaller than the limiting frame.
[0013] Furthermore, the patch body is fixed to the middle of the perspective film, and the sides of the perspective film are fixed to the inner wall of the limiting frame.
[0014] Furthermore, a release paper is connected to the front side of the first sticker, and the release paper is fixed on the corners of the first sticker.
[0015] Furthermore, the side of the first sticker away from the release paper is adhered to the patch body and the limiting frame, wherein the side sticker is folded and stored on the first sticker.
[0016] Compared with the prior art, the lansoprazole transdermal patch provided by the utility model has the following beneficial effects:
[0017] The lansoprazole transdermal patch is provided with a limiting frame connected to the full film, the limiting frame can abut against the skin, and the patch body on the transparent film is limited in the limiting frame, so as to prevent the liquid in the patch body from flowing out. The transparent film connected to the limiting frame is convenient for the user to observe the use status of the patch body. The side film and the full film can be better adhered to the skin through the humidity of the human body surface, so as to prevent the patch from falling off due to hot weather and skin sweating. The viscosity of the transdermal patch is not only increased, but also the damage to the skin is reduced, so that the device is more convenient to use. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present utility model. For ordinary technicians in this field, other drawings can also be obtained based on these drawings.
[0019] Figure 1 A schematic diagram of the overall structure of the utility model in the first perspective when it is opened;
[0020] Figure 2 A schematic diagram of the overall structure of the utility model in the second viewing angle when it is in an open state;
[0021] Figure 3 It is a structural schematic diagram of the utility model in a closed state;
[0022] Figure 4 It is a schematic diagram of the explosion structure of the utility model in the open state.
[0023] Description of reference numerals:
[0024] 1. Side film; 2. Full film; 3. First sticker; 4. Second sticker; 5. Peel-off paper; 6. Transparent film; 7. Limiting frame; 8. Patch body. DETAILED DESCRIPTION
[0025] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described in detail below in conjunction with the accompanying drawings.
[0026] See also Figure 1-4 A lansoprazole transdermal patch includes a full film 2, the middle of the full film 2 is connected to a limiting frame 7, the middle of the limiting frame 7 is connected to a transparent film 6, the outer side of the full film 2 is connected to a side film 1, the front side of the transparent film 6 is connected to a patch body 8 and a first sticker 3, and the side film 1 is folded on the first sticker 3.
[0027] The side film 1, the full film 2 and the transparent film 6 are all made of thin and transparent plastic materials with a certain degree of elasticity. The side film 1 is fixed on the full film 2, and can adhere to the human skin through the connected full film 2, further increasing the closeness of the contact between the limiting frame 7 and the human skin, reducing the probability of liquid flowing out of the limiting frame 7, thereby increasing the airtightness of the device and facilitating better absorption of the drug by the human skin.
[0028] A second sticker 4 is adhered to one end of the side film 1 away from the full film 2, and the full film 2 is fixedly connected to the limiting frame 7, wherein the thickness of the side film 1 and the first sticker 3 are both smaller than the limiting frame 7. The side film 1 connected to the full film 2 increases the contact area with the human skin, improves the adhesion of the patch body 8, and prevents the limiting frame 7 from falling off the human skin. The second sticker 4 connected to the side film 1 makes it easy for the user to open the side film 1, making the device more convenient to use.
[0029] The patch body 8 is fixed to the middle of the transparent film 6 , and the side of the transparent film 6 is fixed to the inner wall of the limiting frame 7 . The transparent film 6 connected in the limiting frame 7 facilitates the user to observe the use status of the patch body 8 .
[0030] The front side of the first sticker 3 is connected with a release paper 5, which is fixed on the corners of the first sticker 3. By connecting the release paper 5 to the first sticker 3, not only the patch body 8 in the limiting frame 7 can be protected, but also the limiting frame 7 can be prevented from being contaminated, thereby increasing the protectiveness of the device.
[0031] See also Figure 3 The side of the first sticker 3 away from the release paper 5 is pasted on the patch body 8 and the limiting frame 7, wherein the side film 1 is folded and stored on the first sticker 3. By folding the side film 1 on the first sticker 3, the side film 1 and the first sticker 3 are pasted and folded into a rectangular shape, which can not only protect the pasting surface of the side film 1, but also reduce the shape of the transdermal patch, making it easier for users to carry.
[0032] Working principle: When in use, the user first pulls the side film 1 away from the first sticker 3, and then pulls the peeling paper 5. The peeling paper 5 drives the first sticker 3 to move and tear the first sticker 3 off the limiting frame 7. The user can then place the patch body 8 against the human skin. At this time, the limiting frame 7 is against the human skin, presses the full film 2, and sticks the full film 2 on the human skin. Finally, tear off the second sticker 4 from the side film 1 and stick the side film 1 on the human skin.
[0033] The above only describes some exemplary embodiments of the present invention by way of illustration. It is undoubted that those skilled in the art can modify the described embodiments in various ways without departing from the spirit and scope of the present invention. Therefore, the above drawings and descriptions are illustrative in nature and should not be construed as limiting the scope of protection of the claims of the present invention.
Claims
1. A lansoprazole transdermal patch, characterized in that: The invention comprises a full film (2), wherein the middle of the full film (2) is connected to a limiting frame (7), the middle of the limiting frame (7) is connected to a transparent film (6), the outer side of the full film (2) is connected to a side film (1), the front side of the transparent film (6) is connected to a patch body (8) and a first sticker (3), and the side film (1) is folded on the first sticker (3).
2. A lansoprazole transdermal patch according to claim 1, characterized in that: The side film (1), the full film (2) and the transparent film (6) are all made of thin and transparent plastic materials and have a certain elasticity. The side film (1) is fixed on the full film (2).
3. A lansoprazole transdermal patch according to claim 1, characterized in that: A second sticker (4) is adhered to one end of the side film (1) away from the full film (2), and the full film (2) is fixedly connected to a limiting frame (7), wherein the thickness of the side film (1) and the first sticker (3) are both smaller than that of the limiting frame (7).
4. A lansoprazole transdermal patch according to claim 1, characterized in that: The patch body (8) is fixed to the middle of the transparent film (6), and the side of the transparent film (6) is fixed to the inner wall of the limiting frame (7).
5. A lansoprazole transdermal patch according to claim 1, characterized in that: The front side of the first sticker (3) is connected with a release paper (5), and the release paper (5) is fixed on the corners of the first sticker (3).
6. A lansoprazole transdermal patch according to claim 1, characterized in that: The side of the first sticker (3) away from the release paper (5) is adhered to the patch body (8) and the limiting frame (7), wherein the side film (1) is folded and stored on the first sticker (3).